Pharmacological management in children and adolescents with pervasive developmental disorder

References

• Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of literature. Res Dev Disabil 2006; 27:254–289.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005; 66:9–18.
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002; 52:805–810.
   PubMed Web of Science ®Google Scholar
• Volkmar F, Cook EH Jr, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1999; 38 (Suppl 12):32–54.
   Google Scholar
• Santosh PS, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet 1999; 354:233–242.
   PubMed Web of Science ®Google Scholar
• Gordon CT, State RC, Nelson JE. A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993; 50:441–447.
   PubMed Web of Science ®Google Scholar
• Remington G, Sloman L, Konstantareas M . Clomipramine vs haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled crossover study. J Clin Psychopharmacol 2001; 21:440–444.
   PubMed Web of Science ®Google Scholar
• Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996; 35:537–544.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Naylor ST, Cohen DJ . Double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorders. Arch Gen Psychiatry 1996; 53:1001–1008.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Kresch LB, Posey DJ. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disabil 2000; 30:427–435.
   PubMed Web of Science ®Google Scholar
• Martin A, Koenig K, Anderson GM. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord 2003; 33:77–85.
   PubMed Web of Science ®Google Scholar
• Hollander E, Phillips A, Chaplin W . A placebo-controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005; 30:582–589.
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in the treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998; 28:303–307.
   PubMed Web of Science ®Google Scholar
• DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002; 44:652–659.
   PubMed Web of Science ®Google Scholar
• Cook EH, Rowlett R, Jaselinkis C. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31:739–745.
   PubMed Web of Science ®Google Scholar
• Namerow LB, Thomas P, Bostic JQ, Prince J, Monuteaux MC. Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr 2003; 24:104–108.
   PubMed Web of Science ®Google Scholar
• Owley T, Walton L, Salt J . An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005; 44:343–348.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective, open-label investigation. J Clin Psychopharmacol 1998; 18:62–66.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996; 57:333–336.
   PubMed Web of Science ®Google Scholar
• Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997; 7:9–15.
   PubMed Web of Science ®Google Scholar
• Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic related dyskinesias in autistic children: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 1997; 36:835–843.
   PubMed Web of Science ®Google Scholar
• Campbell M, Anderson LT, Small AM, Perry R, Green WH, Caplan R. The effects of haloperidol on learning and behavior in autistic children. J Autism Dev Disord 1982; 12:167–175.
   PubMed Web of Science ®Google Scholar
• Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms on autistic children. J Autism Dev Disord 1989; 19:227–239.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl):1–93.
   PubMedGoogle Scholar
• McCracken JT, McGough J, Shah B . Risperidone in children with autism and serious behavioral problems. New Engl J Med 2002; 347:314–321.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Scahill L, Aman MG . Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005; 162:1142–1148.
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162:1361–1369.
   PubMed Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A . Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatr 2004; 114:634–641.
   PubMed Web of Science ®Google Scholar
• Potenza MN, Holmes JP, Kanes SJ. Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999; 19:37–44.
   PubMed Web of Science ®Google Scholar
• Kemner C, Wilemsen-Swinkels SH, de Jonge M. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002; 22:455–460.
   PubMed Web of Science ®Google Scholar
• Malone RP, Cate J, Sheikh RM. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001; 40:887–894.
   PubMed Web of Science ®Google Scholar
• Hollander E, Wasserman S, Swanson EN. A double-blind placebo-controlled pilot study of olanzapine in childhood adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006; 16:541–548.
   PubMed Web of Science ®Google Scholar
• Martin A, Koenig K, Scahill L. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9:99–107.
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK, Gracious BL. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14:287–294.
   PubMed Web of Science ®Google Scholar
• Corson AH, Barkenbus JE, Posey DJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004; 65:1531–1536.
   PubMed Web of Science ®Google Scholar
• Hardan AY, Jou RJ, Handan BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005; 35:387–391.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41:921–927.
   PubMed Web of Science ®Google Scholar
• Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004; 65:110–113.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (FDA) Psychopharmacological Drugs Advisory Committee background document on Zeldox (PDAC 0700.M01). Rockville, MD: Food and Drug Administration; 2000.
   Google Scholar
• Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychiatry 2002; 41:921–927.
   PubMedGoogle Scholar
• Stigler KA, Diener JT, Kohn AE, Erickson CA, Posey DJ, McDougle CJ. A prospective, open-label study of aripiprazole in youth with pervasive developmental disorder not otherwise specified and Asperger's disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19(3):265–74.
   PubMedGoogle Scholar
• Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006; 16:549–560.
   PubMed Web of Science ®Google Scholar
• Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 1996; 153:738.
   PubMed Web of Science ®Google Scholar
• Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001; 62:479–480.
   PubMed Web of Science ®Google Scholar
• Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. J Psychiatry Neurosci 2001; 26:340–341.
   PubMed Web of Science ®Google Scholar
• Quintana H, Birmaher B, Stedge D . Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25:283–294.
   PubMed Web of Science ®Google Scholar
• Handen BL, Johnson CR, Lubetsky M. Efficacy of methylpheni-date among children with autism and symptoms of attention deficit hyperactivity disorder. J Autism Dev Disord 2000; 30: 245–255.
   PubMed Web of Science ®Google Scholar
• Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized controlled crossover trial of methylpheni-date in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62:1266–1274.
   PubMed Web of Science ®Google Scholar
• Jou RJ, Handen BL, Harda AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15: 325–330.
   PubMed Web of Science ®Google Scholar
• Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/ hyper-activity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:599–610.
   PubMed Web of Science ®Google Scholar
• Troost PW, Steenhuis MP, Tuynman-Qua HG. Atomoxetine for attention-deficit hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006; 16:611–619.
   PubMed Web of Science ®Google Scholar
• Arnold LE, Aman MG, Cook AM . Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled cross-over pilot trial. J Am Acad Child Adolesc Psychopharmacol 2006; 45:1196–1205.
   PubMed Web of Science ®Google Scholar
• Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 1987; 7:401–405.
   PubMed Web of Science ®Google Scholar
• Steingard R, Biederman J. Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1987; 26:932–935.
   PubMed Web of Science ®Google Scholar
• Kapetanovic S. Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors. Am J Psychiatry 2007; 164:832–833.
   PubMed Web of Science ®Google Scholar
• Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs placebo in the treatment of repetitive behaviors in autistic spectrum disorder. Int J Neuropsychopharmacol 2006; 9:209–213.
   PubMed Web of Science ®Google Scholar
• Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autistic spectrum disorders. J Clin Psychiatry 2001; 62:530–534.
   PubMed Web of Science ®Google Scholar
• Hellings JA, Weckbaugh M, Nickel EJ . A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005; 15:682–692.
   PubMed Web of Science ®Google Scholar
• Campbell M, Overall JE, Small AM . Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989; 28:200–206.
   PubMed Web of Science ®Google Scholar
• Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child and Adolesc Psychiatry 1993; 32:1283–1291.
   PubMed Web of Science ®Google Scholar
• Kolmen BK, Feldman HM, Handen BL . Naltrexone in young autistic children: a double-blind placebo-controlled crossover-study. J Am Acad Child Adolesc Psychiatry 1995; 34:223–231.
   PubMed Web of Science ®Google Scholar
• Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997; 36:1570–1578.
   PubMed Web of Science ®Google Scholar
• Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999; 38:587–593.
   PubMed Web of Science ®Google Scholar
• Willemsen-Swinkels SHN, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39:1023–1031.
   PubMed Web of Science ®Google Scholar
• Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic Disorder. J Clin Psychopharmacol 1992; 12:322–327.
   PubMed Web of Science ®Google Scholar
• Fankhauser MP, Karamanchi VC, German MLEA. A double blind placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992; 53:77–82.
   PubMed Web of Science ®Google Scholar
• Posey DJ, Puntney JI, Sasher TM, Kem DL, McDougle CJ. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004; 14:233–241.
   PubMed Web of Science ®Google Scholar
• Scahill L, Aman MG, McDougle CJ . A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:589–598.
   PubMed Web of Science ®Google Scholar
• King BH, Wright DM, Handen BL . Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001; 40:658–665.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorder. Psychopharmacol 2007; 191:141–147.
   PubMed Web of Science ®Google Scholar
• Owley T, Salt J, Guter S . A prospective open-label trial of memantine in the treatment of cognitive, behavioral and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16:517–524.
   PubMed Web of Science ®Google Scholar
• Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. J Child Neurol 2007; 22:574–579.
   PubMed Web of Science ®Google Scholar
• Wasdell MB, Jan JE, Bomben MM . A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008; 44:57–64.
   PubMed Web of Science ®Google Scholar
• Paavonen EJ, Nieminen-von Wendt T, Vanhala R, Aronen ET, von Wendt L. Effectiveness of melatonin in the treatment of sleep disturbance in children with asperger disorder. J Child Adolesc Psychopharmacol 2003; 13:38–95.
   Google Scholar
• Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord 2006; 36:741–752.
   PubMed Web of Science ®Google Scholar
• Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 2008; 23:482–485.
   PubMed Web of Science ®Google Scholar
• Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006; 32:585–589.
   PubMed Web of Science ®Google Scholar
• Hovath K, Stefanatos G, Sokolski K, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minority Physicians 1998; 9: 9–15.
   PubMedGoogle Scholar
• Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev 2005; (3):CD003495.
   PubMedGoogle Scholar